Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle
Authors:
- 19 November 2002
- journal article
- clinical trial
- Published by Wiley in Veterinary Ophthalmology
- Vol. 5 (4) , 253-262
Abstract
The objective of this study was to evaluate the changes in intraocular pressure (IOP) in glaucomatous dogs after instillations of 0.2% brimonidine once, twice and three times daily in single day studies, and after twice and three times daily for 4 days in multiple dose studies. We studied eight Beagles with inherited primary open angle glaucoma. Applanation tonometry (IOP), pupil size (PS) and heart rate (HR) measurements were obtained at 8 am, 10 am, 1 pm, 3 pm and 5 pm. The studies were divided into: eight glaucoma dogs and five of the eight dogs that demonstrated greater response to 0.2% brimonidine. Single‐dose drug studies are divided into placebo (0.5% methylcellulose), 0.2% brimonidine administered once daily (8 am); twice daily (8 am and noon); and three times daily (8 am, noon and 5 pm). The 5‐day multiple‐dose studies included: day 1, no drug; and 4 days, 0.2% brimonidine instillations either twice daily (8 am and 2 pm) or three times daily (8 am, 2 pm and 9 pm). Statistical comparisons between drug groups included control (nondrug) and treated (placebo/0.2% brimonidine) eyes for both single‐ and multiple‐dose studies. The mean ± SEM diurnal decrease in IOP in the eight glaucomatous Beagles for the control and placebo eyes were 3.4 ± 4.7 and 5.4 ± 2.8 mmHg, respectively. The mean ± SEM diurnal decrease in IOP after 0.2% brimonidine once, twice and three times daily was 6.4 ± 3.5, 8.0 ± 6.1 and 9.8 ± 8.1 mmHg, respectively; this trend was not significant statistically. Significant miosis occurred starting 2 h postinstillations, and the resultant mean ± SD pupil size was 2.7 ± 0.3 mm. A significant decrease in heart rate also occurred (12%). In the five most responsive dogs the changes in PS and HR during these studies were similar to the larger group, but significant decreases in IOP occurred at most measurement times. In the multiple‐dose study with 0.2% brimonidine twice daily the mean ± SEM decrease in IOP for day 1 to day 4 was 5.0 ± 1.3, 5.7 ± 1.3, 1.4 ± 3.3 and 4.9 ± 1.3 mmHg, respectively. When 0.2% brimonidine was instilled three times daily the mean ± SEM diurnal IOP decrease was from day 1 to day 4 and was 0.75 ± 1.3, 2.4 ± 1.5, 1.2 ± 2.7 and 1.4 ± 1.8 mmHg, respectively. The mean change in pupil diameter was 1.3 ± 0.5 mm. Decrease in HR averaged 22%. In the same single‐dose studies with the five most responsive dogs, PS and HR were similar, but the decreases in IOP were significant at more measurement intervals. We conclude that 0.2% brimonidine produces a decrease in IOP in dogs, a statistically significant miosis, and a reduced heart rate (12–22%). However, because of the limited drug‐induced ocular hypotension, brimonidine should be combined with other drugs when used for the glaucomas in the dog.Keywords
This publication has 14 references indexed in Scilit:
- Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive AgentsArchives of Ophthalmology (1950), 1999
- Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patientsAmerican Journal of Ophthalmology, 1999
- Comparison of the Efficacy of Apraclonidine and Brimonidine as Aqueous Suppressants in HumansArchives of Ophthalmology (1950), 1998
- BrimonidineJournal of Glaucoma, 1997
- Brimonidine TartrateOphthalmology, 1997
- Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studiesSurvey of Ophthalmology, 1996
- Preclinical evaluation of brimonidineSurvey of Ophthalmology, 1996
- Effects of Brimonidine on Aqueous Humor Dynamics in Human EyesArchives of Ophthalmology (1950), 1995
- The Cardiovascular, Pulmonary, and Ocular Hypotensive Effects of 0.2% BrimonidineArchives of Ophthalmology (1950), 1995
- Ocular effects of a relatively selective α2 agonist (UK-14, 304-18) in cats, rabbits and monkeysCurrent Eye Research, 1986